Healthcare shares were among the worst performers Tuesday, as Wall Street paused from its recent volatility. The market had seen dramatic swings since President Trump's tariff announcement on April 2.
Johnson & Johnson exceeded expectations for first-quarter earnings and revenue, raising its full-year sales outlook due to acquisition of drug developer Intra-Cellular Therapies.
J&J's 1Q report bodes well for the medical-technology sector, JPMorgan analysts said in a research note, citing the company's positive commentary on overall demand and preliminary thoughts on tariffs.
Write to Paulo Trevisani at paulo.trevisani@wsj.com
(END) Dow Jones Newswires
April 15, 2025 17:01 ET (21:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.